Article Per Year (5 Year)
p-Index From 2021 - 2026
0.882
P-Index
This Author published in this journals
All Journal journal of internal medicine The Indonesian Biomedical Journal Molecular and Cellular Biomedical Sciences (MCBS) Biomolecular and Health Science Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Mutiara: Jurnal Penelitian dan Karya Ilmiah
Made Putra Sedana
Hematology Oncology Medic Sub-specialist Program, Department Of Internal Medicine, Faculty Of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya
Religion Humanities Biochemistry, Genetics & Molecular Biology Computer Science & IT Dentistry Electrical & Electronics Engineering Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Neuroscience Public Health Other

Published : 10 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 10 Documents
Search

 1 
ASOSIASI CA 125 DENGAN RESPON TERAPI PADA PENDERITA LIMFOMA NON-HODGKIN AGRESIF YANG MENDAPAT KEMOTERAPI CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE (CHOP) S, Merlyna; Mulyono, Adi; -, Ugroseno; Putra Sedana, Made; Ashariati, Ami; -, Sugianto; -, Boediwarsono; -, Soebandiri
journal of internal medicine Vol. 12, No. 3 September 2011
Publisher : journal of internal medicine

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (449.126 KB)

Abstract

Cancer antigen (CA) 125 is a glycoprotein produced by epithelial ovarium tumors and mesothelial cells, its levels alsohave been shown to be elevated in patients with Non-Hodgkin!s Lymphoma (NHL). Several papers have reported anassociation of high CA 125 serum levels with advanced NHL as well as relationship between high CA 125 values and pooroutcome. This study aimed to determine association between CA 125 levels (> 35 U/ml) with normal CA 125 (  35 U/ml)to the respone of NHL patients receiving chemotherapy CHOP. An observational analytic prospective study was done in40 patients with NHL at Dr Soetomo Hospital Surabaya. The patient were recruited from both inpatient and outpatientclinic and the initial CA 125 level had determined before the patients received chemotherapy with Cyclophosphamide,Doxorubicin, Vincristine and Prednisone (CHOP). Of the 40 patients who included in this study, 62.5% were male, 37.5%were female, the average age 43,45 years, the most kind of histophatology result were diffuse large cell, cleaved or noncleaved cell (47.5%). There was a signiÞ cant association between CA 125 levels with therapy respone groups (responiveand unresponive), with signiÞ cancy 0.001 (OR 23.22; CI 95%), and with therapy respone groups (CR, PR, NC, PD) withsigniÞ cancy 0.013. The group with normal CA 125 levels (  35 U/ml), had better respone, it was around 95% responive(CR = 35%, PR = 60%) and 5% unresponive (NC = 5%, PD = 0%) than the group who had high CA 125 levels (> 35U/ml), it was only 45% responive (CR = 15%, PR = 30% and 55% unresponive (NC = 50%, PD = 5%). As a conclusion,levels of CA 125 (> 35 U/ml) perhaps could be a negative prognostic factor to predict the CHOP chemotherapy responein NHL patients.
PENYAKIT MIELOPROLIFERATIF Putra Sedana, Made; Wulansari, T. Ivone
journal of internal medicine Vol. 8, No. 1 Januari 2007
Publisher : journal of internal medicine

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (313.206 KB)

Abstract

Myeloproliferative disorder (MPD) represent a group of disease marked by cellular proliferation of one or morehaematologic stem cells which include polycythemia vera, essential thrombocythemia, chronic idiopathic myelofibrosis withmyeloid metaplasia / MMM, hypereosinophillic syndrome / HES, unclassified myeloproliferative disease / U-Mpd, chronicmyelogenous leukemia / CML and chronic neutrophylic leukemia / CNL. The incidence and pathogenesis are still unknown.Chronicity which alterable to aggressive phase become acute leukemia and clonal cytogenetic abnormalities in erythroblast,neutrophyl, basophyl, macrophage, megakaryocytes and B-lymphocytes, but not in fibroblast are characteristics of the disease.Haematopoeisis is marked by autonomically growth and myeloid hyperplasia in bone marrow. Bone marrow aspiration showtrilineage hypercellularity. The complications include thrombotic phenomenon, micro and macrovascular arteries thrombosis,bleeding phenomenon, hypercatabolism and transformation into acute myelogenous leukemia / AML. Pseudocoagulopathy,pseudohyperkalemia, pseudohyperacydphosphatemia, pseudohypoglicemia and pseudohypoxemia can be seen.
Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients Merlyna Savitri; Ugroseno Yudho Bintoro; Made Putra Sedana; Muhammad Noor Muhammad; Pradana Zaky Romadhon; Putu Niken Ayu Amrita; Andi Yasmin Wijaya; Winona May Hendrata; Ami Ashariati Prayogo
The Indonesian Biomedical Journal Vol 12, No 2 (2020)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v12i2.1142

Abstract

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21
CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya Rina Syarifah Salma; Made Putra Sedana; S. Ugroseno Yudho
Biomolecular and Health Science Journal Vol. 1 No. 2 (2018): Biomolecular and Health Science Journal
Publisher : Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (178.026 KB) | DOI: 10.20473/bhsj.v1i2.9244

Abstract

Introduction: Non-Hodgkin Lymphoma (NHL) is a group of lymphoid-derived malignant disease with heterogenic biological and clinical manifestations. For over 30 years, CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) has been the first choice of chemotherapy for aggressive NHL. Later in 1997 Rituximab as anti-CD20 monoclonal antibody was introduced and then combined with CHOP as R-CHOP. The objective of this study is to acknowledge the response of the CHOP and R-CHOP therapy in Non-Hodgkin Lymphoma patients at Dr. Soetomo General Hospital.Methods: The design of this study was retrospective observational study using secondary data obtained from patient’s medical records from 2011 to 2015. The data selected from the medical records are the result of the therapy, as well as patient’s gender and age. Results: The results of patients’ therapy were classified into four categories: The study showed that 51.28% patients had Complete Response, followed by Partial Response (28.21%), Progressive Disease (17.95%), and No Change (2.56%). Sample characteristics showed male patients in higher percentage (66.67%), and the majority of patients’ age between 51-60 years old (30.77%). The use of CHOP and R-CHOP regiment were 76.92% and 20,52% respectively.Conclusion: Most of the patients had a complete response. The CHOP regiment is more commonly used in patients compared to R-CHOP.
Difference Expressions CD34 in Acute Myeloid Leukemia Cell Culture in the Administration of Cytarabine-Daunorubicine Dose Standards Muhammad Saiful Rahman; Paulus Budiono Notopuro; Suprapto Ma'at; Made Putra Sedana; Arifoel Hajat
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 27, No 2 (2021)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v27i2.1623

Abstract

The cure rate for patients with Acute Myeloid Leukemia (AML) is 20-75%. Standard-dose cytarabine + (SDAC)-daunorubicine gives a remission rate of ± 60%, and the case of relapse is frequently found. In-vivo CD34 expression is a reliable and straightforward test that must evaluate AML patients' response to predict the response of chemotherapy + induction phase accurately. Differences in in-vitro CD34 expression are expected to be able to predict chemosensitivity in AML patients. An experimental post-test-only control group study was conducted from May to December 2019, and 8 AML subjects were found. Peripheral Blood Mononuclear Cells (PBMC) were isolated from peripheral blood samples of patients with AML collected in EDTA tubes. The PBMC isolated from peripheral blood were divided into two groups, and each group contained 106 PBMC cells in culture media. The control group (without treatment) and the SDAC-daunorubicine group were 0 + incubated for 4 hours at 37 C with a 5% CO2 atmosphere. The expression of CD34 was measured using FACSCalibur™, while + CD34+ percentage was calculated with CellQuest™ software. The percentage of CD34 in the control, SDAC + DNR, showed a significant difference with p < 0.001. This study showed a significant difference between the control group and the group + administered with the standard dose of cytarabine-daunorubicine with p < 0.001. The average CD34 expression in the + SDAC-DNR treatment group was higher than in the control group. CD34 markers cannot be used as predictors of chemosensitivity in the administration of chemotherapy.
Pancytopenia and Progressive Splenomegaly in Patient with Disseminated Histoplasmosis Paulus Budiono Notopuro; Arifoel Hajat; Made Putra Sedana
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 27, No 2 (2021)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v27i2.1621

Abstract

Disseminated histoplasmosis is a severe manifestation of fungal infection caused by Histoplasma capsulatum. It usuallyoccurs in a patient with an immunodeficiency state. With the increase of HIV infection and the use of immunosuppressantdrugs lately, its prevalence also increases. A case of 43 years old female with prolonged fever, pancytopenia, and massiveprogressive splenomegaly. The diagnosis of disseminated histoplasmosis and the secondary hemophagocytic syndromewas made based on bone marrow examination that showed increased hemophagocytic processes and multipleintracytoplasmic H.capsulatum. She had been treated with Itraconazole 200 mg for three months. In the first month'sevaluation, her complete blood count improved without any transfusions, and the size of her spleen size decreased. She hadbeen fully recovered after the completion of 3-month treatment.
Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months Andy Purnomo; Ugroseno Yudho Bintoro; Made Putra Sedana; Ami Ashariati
Molecular and Cellular Biomedical Sciences Vol 3, No 2 (2019)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v3i2.56

Abstract

Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent of Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis.Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed using Fisher exact test which was considered significant if p<0.05.Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin was 9.1 g/dL, median leukocyte was 180x109 /L, median thrombocyte was 645x109 /L, median eosinophil was 2.9%, median basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic response with imatinib.Keywords: Hasford score, hematologic response, CML, imatinib
Pancytopenia and Progressive Splenomegaly in Patient with Disseminated Histoplasmosis Paulus Budiono Notopuro; Arifoel Hajat; Made Putra Sedana
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 27 No. 2 (2021)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v27i2.1621

Abstract

Disseminated histoplasmosis is a severe manifestation of fungal infection caused by Histoplasma capsulatum. It usually occurs in a patient with an immunodeficiency state. With the increase of HIV infection and the use of immunosuppressant drugs lately, its prevalence also increases. A case of 43 years old female with prolonged fever, pancytopenia, and massive progressive splenomegaly. The diagnosis of disseminated histoplasmosis and the secondary hemophagocytic syndrome was made based on bone marrow examination that showed increased hemophagocytic processes and multipleintracytoplasmic H.capsulatum. She had been treated with Itraconazole 200 mg for three months. In the first month's evaluation, her complete blood count improved without any transfusions, and the size of her spleen size decreased. She had been fully recovered after the completion of 3-month treatment.
Difference Expressions CD34 in Acute Myeloid Leukemia Cell Culture in the Administration of Cytarabine-Daunorubicine Dose Standards Muhammad Saiful Rahman; Paulus Budiono Notopuro; Suprapto Ma'at; Made Putra Sedana; Arifoel Hajat
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 27 No. 2 (2021)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v27i2.1623

Abstract

The cure rate for patients with Acute Myeloid Leukemia (AML) is 20-75%. Standard-dose cytarabine + (SDAC)-daunorubicine gives a remission rate of ± 60%, and the case of relapse is frequently found. In-vivo CD34 expression is a reliable and straightforward test that must evaluate AML patients' response to predict the response of chemotherapy + induction phase accurately. Differences in in-vitro CD34 expression are expected to be able to predict chemosensitivity in AML patients. An experimental post-test-only control group study was conducted from May to December 2019, and 8 AML subjects were found. Peripheral Blood Mononuclear Cells (PBMC) were isolated from peripheral blood samples of patients with AML collected in EDTA tubes. The PBMC isolated from peripheral blood were divided into two groups, and each group contained 106 PBMC cells in culture media. The control group (without treatment) and the SDAC-daunorubicine group were 0 + incubated for 4 hours at 37 C with a 5% CO2 atmosphere. The expression of CD34 was measured using FACSCaliburâ„¢, while + CD34+ percentage was calculated with CellQuestâ„¢ software. The percentage of CD34 in the control, SDAC + DNR, showed a significant difference with p < 0.001. This study showed a significant difference between the control group and the group + administered with the standard dose of cytarabine-daunorubicine with p < 0.001. The average CD34 expression in the + SDAC-DNR treatment group was higher than in the control group. CD34 markers cannot be used as predictors of chemosensitivity in the administration of chemotherapy.
Perbaikan Manajemen Bank Sampah Di Desa Selat Untuk Meningkatkan Nilai Tambah Pengolahan Sampah Menjadi Pupuk Organik Dengan Aplikasi Berbasis Android Komang Gede Darmayasa; Made Putra Sedana; I Putu Prasna Mahardika; I Kadek Heri Suardan; I Dewa Gede Andreano Eldo; Nengah Taksu Yusaramana; I Nyoman Mahatma Yogeshvara; I Kadek Dhananjaya Dana Putra; Made Naradha Adithya; I Made Dwijaksana; Made Agus Putra Harta Narayana; Putu Pande Devaryana Putra; Made Rasmika Werdhi Nugraha; I Putu Gede Raditya Wikadhyana; I Dewa Gede Agung Astina Wirayudha; Made Sucipta
Mutiara : Jurnal Penelitian dan Karya Ilmiah Vol. 1 No. 5 (2023): Oktober: Mutiara : Jurnal Penelitian dan Karya Ilmiah
Publisher : STAI YPIQ BAUBAU, SULAWESI TENGGARA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59059/mutiara.v1i5.465

Abstract

The waste problem in Selat Village has caused severe environmental pollution. The main cause of this problem is because most of the people in Selat Village have not been able to carry out proper and integrated waste management, resulting in uncontrolled accumulation of waste. The general objective of this research is to initiate the progress of village areas in Indonesia regarding Waste Digitalization. The results of this study indicate that the Wita Bersih Application can shorten the time and make it easier for the Selat Village garbage bank in processing plastic waste.
Co-Authors Adi Mulyono Ami Ashariati Andi Yasmin Wijaya Andy Purnomo Arifoel Hajat Bintoro, Siprianus Ugroseno Yudho Boediwarsono - I Dewa Gede Agung Astina Wirayudha I Dewa Gede Andreano Eldo I Kadek Dhananjaya Dana Putra I Kadek Heri Suardan I Made Dwijaksana I Nyoman Mahatma Yogeshvara I Putu Gede Raditya Wikadhyana I Putu Prasna Mahardika Komang Gede Darmayasa Made Agus Putra Harta Narayana Made Naradha Adithya Made Rasmika Werdhi Nugraha Made Sucipta Merlyna S Merlyna Savitri Muhammad Noor Muhammad Muhammad Saiful Rahman Nengah Taksu Yusaramana Notopuro, Paulus Budiono Putu Niken Ayu Amrita Putu Pande Devaryana Putra Rina Syarifah Salma Romadhon, Pradana Zaky Soebandiri - Sugianto - Suprapto Ma&#039;at Suprapto Ma'at T. Ivone Wulansari Ugroseno - Ugroseno Yudho Bintoro Ugroseno Yudho Bintoro Winona May Hendrata